Lantheus (LNTH) Set to Announce Earnings on Thursday

Lantheus (NASDAQ:LNTH - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $1.34 per share for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, topping analysts' consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The business had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Trading Down 0.0 %

LNTH stock traded down $0.01 during midday trading on Thursday, reaching $65.20. The company's stock had a trading volume of 602,999 shares, compared to its average volume of 1,036,479. The business's 50-day simple moving average is $61.31 and its 200-day simple moving average is $62.75. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. Lantheus has a 52 week low of $50.20 and a 52 week high of $100.85. The stock has a market cap of $4.47 billion, a PE ratio of 14.05 and a beta of 0.53.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LNTH shares. B. Riley raised their target price on Lantheus from $95.00 to $99.00 and gave the stock a "buy" rating in a report on Thursday, April 18th. StockNews.com raised Lantheus from a "hold" rating to a "buy" rating in a research report on Saturday, January 13th. JMP Securities reissued a "market outperform" rating and set a $100.00 target price on shares of Lantheus in a research note on Friday, February 23rd. Finally, Truist Financial reissued a "buy" rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus price target of $104.71.

Insider Transactions at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company's stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now owns 251,643 shares of the company's stock, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders sold a total of 94,545 shares of company stock worth $6,169,936 in the last three months. Insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.